Evaluating the bioequivalence of levetiracetam brand and generic oral tablets available in the Saudi market in vivo
Background: Epilepsy is a common global neurological disorder. About 30% of epileptic patients are managed with anti-epileptic Drugs (AEDs). Since 2000, Levetiracetam (LEV) has been marketed around the world as an AED under the brand name Keppra, and recently more generics are found in the Saudi mar...
Saved in:
Main Authors: | Danah ALRabeeah (Author), Aliyah Almomen (Author), Nourah Alzoman (Author), Maria Arafah (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Safety of switching from brand-name to generic levetiracetam in patients with epilepsy
by: Bosak M, et al.
Published: (2017) -
Ceramide expression in relation to breast cancer molecular subtypes in Saudi women
by: Aliyah Almomen, et al.
Published: (2021) -
Sampling times and genotyping concerns in bioequivalence evaluation of branded and generic formulations
by: Zhao XY, et al.
Published: (2013) -
Quality assessment of different brands of atorvastatin tablets available in Riyadh, Saudi Arabia
by: Ali AlMuhsin, et al.
Published: (2022) -
Evaluation of the quality and pharmacoeconomics of some generic drugs versus their reputed counterpart brands in the Saudi market
by: Farouk M Sakr, et al.
Published: (2016)